In den neuen europäischen Leitlinien wird das LDL-Cholesterin als das wichtigste Behandlungsziel hervorgehoben. Bevölkerungsbezogene Präventionsmaßnahmen werden stärker betont und die Diagnostik und Therapie genetischer Dyslipidämien detailliert abgehandelt.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Reiner Z, Catapano AL, De Backer G et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769–818
Catapano AL, Graham I, De Backer G et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016 Aug 27. doi: 10.1093/eurheartj/ehw272
Zylka-Menhorn V. Neue ESC/EAS-Leitlinie Dyslipidämie: Es bleibt — fast — alles beim Alten. Dtsch Arztebl. 2016;113(37): A–1596 / B-1347 / C-1323
Stone NJ, Robinson JG, Lichtenstein AH et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1–45
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Klose, G. Die 2016 ESC/EAS-Leitlinien zur Behandlung von Dyslipidämien. CV 16, 47–49 (2016). https://doi.org/10.1007/s15027-016-1032-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15027-016-1032-6